Tools for Practice Outils pour la pratique


#258 Stealth style transmission? Covert data on COVID-19


CLINICAL QUESTION
QUESTION CLINIQUE
What is the evidence for asymptomatic transmission of COVID-19 (including those who will remain asymptomatic and those who are early and not symptomatic yet)?


BOTTOM LINE
RÉSULTAT FINAL
Transmission of COVID-19 can occur in people who are currently asymptomatic. Case reports suggest this occurs in 6-13% of cases, although modelling suggests this might be higher. The importance of asymptomatic transmission is heightened by reports that ~50% of carriers are asymptomatic when an entire population (example cruise ship) is tested. Physical distancing should assist in preventing transmission from asymptomatic individuals.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Transmission: 
  • 468 COVID-19 transmission cases in China.1 
    • In 13% (59/468) of cases, the secondary patient reported symptoms before the source. 
  • 157 COVID-19 transmission cases in Singapore.2 
    • In 6% (10/157) of cases, the secondary patient reported symptoms 1-3 days before the source. 
  • Other case reports of pre-symptomatic/asymptomatic transmission in family, business and hospital settings reported.3-7 
Proportion of COVID-19 positive patients who are asymptomatic at time of testing: 
  • From testing all individuals in a closed environment: 
    • 331/712 (47%): cruise ship passengers.8 
    • 13/23 (57%): long-term care residents.9 
    • 50-75%: entire small town in Italy (Numbers not reported).10 
  • Modelling studies estimate that pre-symptomatic or asymptomatic transmission may occur in 23-62% of cases.11-13 
Limitations: 
  • Difference between asymptomatic (those who test positive for COVID-19, but never become symptomatic7,14) and pre-symptomatic (transmission from the source to a secondary patient before the source develops symptoms) often not clearly reported. 
  • Recall bias of symptoms, dates and exposures. 
  • Presumption that symptomatic exposure ‘trumps’ asymptomatic transmission. 
  • Asymptomatic cases not always identified. 
  • Assumption that those who test positive for COVID-19 are infectious. 
Incubation period and time to spread: 
  • The mean incubation period (time before person becomes symptomatic) is ~5 days, may be up to 14 days.15 
  • Infected individuals can transmit ~4-8 days after becoming infected, possibly before symptoms develop.11,12,16-19 
Viral Load: 
  • Viral loads of asymptomatic and symptomatic patients appear similar.9,20 
  • Viral load is highest at symptom onset or in the first week.13,20-24 
    • Theoretically may increase pre-symptomatic transmission.13 
    • In contrast, peak viral load of MERS and SARS patients is ~ 7-10 days after symptom onset.22 
Context: 
  • Initially WHO suggested that pre-symptomatic and asymptomatic infections were "rare/not a major driver of transmission"25, but now recognize it may occur.11 
  • Physical distancing and other methods should reduce transmission between asymptomatic individuals. 


Latest Tools for Practice
Derniers outils pour la pratique

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Read Lire 0.25 credits available Crédits disponibles

#375 Pharm for Fibro: Can antidepressants ease the pain?

Do antidepressants reduce pain in patients with fibromyalgia?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Christina Korownyk MD CCFP
  • Michael R Kolber MD CCFP MSc

1. Du Z, Xu X, Wu Y, et al. Serial interval of COVID-19 among publicly reported confirmed cases. Emerg Infect Dis. 2020 Jun [April 9, 2020]. https://doi.org/10.3201/eid2606.200357

2. Wei W, Li Z, Chiew CJ, et al. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020. Epub April 1, 2020. https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6914e1-H.pdf Accessed April 9, 2020.

3. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020 Jul [April 9, 2020]. https://doi.org/10.3201/eid2607.200718

4. Qian G, Yang N, Ma AHY, et al. A COVID-19 Transmission within a family cluster by presymptomatic infectors in China. Clin Infect Dis. 2020 Mar 23. pii: ciaa316. doi: 10.1093/cid/ciaa316. [Epub ahead of print]

5. Li P, Fu JB, Li KF, et al. Transmission of COVID-19 in the terminal stage of incubation period: a familial cluster. Int J Infect Dis. 2020 Mar 16. pii: S1201-9712(20)30146-6. doi: 10.1016/j.ijid.2020.03.027. [Epub ahead of print]

6. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020; 382:970-971. DOI: 10.1056/NEJMc2001468

7. Zhang J, Tian S, Lou J, et al. Familial cluster of COVID-19 infection from an asymptomatic. Crit Care. 2020;24(1):119. doi: 10.1186/s13054-020-2817-7.

8. Moriarty L, Plucinski M, Marston B, et al. Public Health Responses to COVID-19 Outbreaks on Cruise Ships - Worldwide, February-March 2020. MMWR Morb Mortal Wkly Rep. 2020;69:347-352. DOI: http://dx.doi.org/10.15585/mmwr.mm6912e3

9. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69:377-381. DOI: http://dx.doi.org/10.15585/mmwr.mm6913e1

10. Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. BMJ. 2020;368:m1165 doi:https://doi.org/10.1136/bmj.m1165 (Published 23 March 2020)

11. Liu Y, Funk S, Flasche S. The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019 [version 1; peer review: awaiting peer review]. Wellcome Open Res. 2020, 5:58 (https://doi.org/10.12688/wellcomeopenres.15788.1)

12. Tapiwa G, Cécile K, Dongxuan C, et al. Estimating the generation interval for COVID-19 based on symptom onset data. medRxiv preprint. https://www.medrxiv.org/content/10.1101/2020.03.05.20031815v1.full.pdf Accessed April 7, 2020.

13. He X, Lau E, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. med Rxiv preprint. https://www.medrxiv.org/content/10.1101/2020.03.15.20036707v2. Accessed April 9, 2020.

14. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report - 73. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_2 Accessed April 9, 2020.

15. Lauer SA, Grantz KH, Bi Q et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020 Mar 10. doi: 10.7326/M20-0504. [Epub ahead of print]

16. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. Int J Infect Dis. 2020 Mar 4. pii: S1201-9712(20)30119-3. doi: 10.1016/j.ijid.2020.02.060. [Epub ahead of print]

17. Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infect Dis. 2020 Apr 2. pii: S1473-3099(20)30230-9. doi: 10.1016/S1473-3099(20)30230-9. [Epub ahead of print]

18. Tindale L, Coombe M, Stockdale J, et al. Transmission interval estimates suggest pre-symptomatic spread of COVID-19. med Rxiv preprint. https://www.medrxiv.org/content/10.1101/2020.03.03.20029983v1.full.pdf  Accessed April 9, 2020.

19. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.

20. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020 Mar 19;382(12):1177-1179. doi: 10.1056/NEJMc2001737. Epub 2020 Feb 19.

21. Hill K, Russell C, Clifford S, et al. The index case of SARS-CoV-2 in Scotland: a case report. J Infection (2020). doi: https://doi.org/10.1016/j.jinf.2020.03.022.

22. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 Mar 23. pii: S1473-3099(20)30196-1. doi: 10.1016/S1473-3099(20)30196-1. [Epub ahead of print]

23. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020 Mar 3. doi: 10.1001/jama.2020.3204. [Epub ahead of print]

24. Wölfel R, Corman V, Guggemos W et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 Apr 1. doi: 10.1038/s41586-020-2196-x. [Epub ahead of print]

25. WHO. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. 

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.